galectin.jpg
Galectin Therapeutics to Present Clinical Data at The Liver Meeting® 2017 Demonstrating the Ability of Non-Invasive Test to Identify Clinically Significant Portal Hypertension in Patients with Compensated NASH Cirrhosis
October 20, 2017 08:30 ET | Galectin Therapeutics Inc.
NORCROSS, Ga., Oct. 20, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today that Dr. Raj...
galectin.jpg
Galectin Therapeutics CEO Peter G. Traber, M.D. Named Chair of the Conference for NASH Summit Europe 2017
September 25, 2017 08:30 ET | Galectin Therapeutics
NORCROSS, Ga., Sept. 25, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced Peter G. Traber, M.D., the...
Galectin Therapeutics, Inc. Logo
Galectin Therapeutics launches the Liver Line, an online community and publication on liver health and liver disease
May 03, 2017 08:30 ET | Galectin Therapeutics
NORCROSS, Ga., May 03, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced the launch of the Liver...
galectin.jpg
Galectin Therapeutics Issues Statement Regarding GALTW and GALTU
March 23, 2017 08:30 ET | Galectin Therapeutics
NORCROSS, Ga., March 23, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today that trading will be...
Surefire Receives Regulatory Approval for Infusion Systems and Guiding Catheters in Mexico
March 20, 2017 06:00 ET | Surefire Medical, Inc.
WESTMINSTER, Colo., March 20, 2017 (GLOBE NEWSWIRE) -- Surefire Medical, Inc., the developer of site-specific delivery devices for the Interventional Oncology market, announced today that the...
Clinical Data Shows Surefire Technology Achieved 79% Objective Response versus 37% Using a Standard Microcatheter in Treating Primary Liver Cancer
March 08, 2017 06:00 ET | Surefire Medical, Inc.
Study presented at SIR 2017 Annual Scientific Meeting WASHINGTON, March 08, 2017 (GLOBE NEWSWIRE) --  Surefire Medical, Inc. today announced that clinical data presented at the Society for...
Surefire Medical Launches New Flexion Guiding Catheter with Nitinol Tip for Better Shape Retention, Improved Back-up Support
March 06, 2017 06:00 ET | Surefire Medical, Inc.
WASHINGTON, March 06, 2017 (GLOBE NEWSWIRE) -- Surefire Medical, Inc. today announced the launch of the new Flexion Guiding Catheter at the Society for Interventional Radiology (SIR) meeting in...
galectin.jpg
Galectin Therapeutics to Present at BIO CEO & Investor Conference
February 08, 2017 08:30 ET | Galectin Therapeutics
NORCROSS, Ga., Feb. 08, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Harold...
galectin.jpg
Galectin Therapeutics to Webcast Corporate Update At Annual Meeting of Stockholders
December 08, 2016 08:00 ET | Galectin Therapeutics
NORCROSS, Ga., Dec. 08, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that the Company...
IMG_0349-Edit-hires-1.jpg
Mats Wahlström Joins Surefire Medical Board of Directors
November 30, 2016 06:00 ET | Surefire Medical, Inc.
WESTMINSTER, Colo., Nov. 30, 2016 (GLOBE NEWSWIRE) -- Surefire Medical, Inc. today announced that Mats Wahlström is joining the company’s Board of Directors and will serve as chairman. Wahlström...